The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study
Open accessAbstract
Background Patients with homozygous familial hypercholesterolemia (HoFH) respond inadequately to existing drugs. We conducted a phase 3 study to assess the efficacy and safety of the microsomal triglyceride transfer protein inhibitor lomitapide in adults with HoFH. Methods Twenty-nine subjects enrolled into a single-arm, open-label study and maintained current lipid lowering therapy from six weeks before baseline through at least week 26. Lomitapide dose was escalated based on safety and tolerability from 5 mg to a maximum of 60 mg/day. The primary endpoint was mean percent change from baseline in LDL-C at week 26, after which patients remained on lomitapide through week 78 for safety assessment. Findings Twenty-three subjects completed weeks 26 and 78. The median dose of lomitapide was 40 mg/day. LDL-C was reduced by 50% from baseline at week 26 (4·3 ± 2·5 mmol/L vs. 8·7 ± 2·9 mmol/L, p<0.0001). Eight subjects achieved LDL-C <2·6 mmol/L at this time point. LDL-C was reduced by 44% at week 56 and 38% at week 78 (p<0.0001 for both). Gastrointestinal symptoms were the most common adverse event. Four patients had aminotransaminase > 5× ULN that resolved after dose reduction or temporary interruption of lomitapide. No subject permanently discontinued treatment due to liver abnormalities. Liver fat content assessed by nuclear magnetic resonance spectroscopy (NMRS; n=20) was 1·0 ± 1·3 % at baseline, 8·6 ± 8·1% at week 26 and remained stable up to week 78 (8·3± 5·3%). Interpretation These data demonstrate that lomitapide had a robust and durable efficacy in lowering LDL-C in patients with HoFH with an acceptable safety and tolerability profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Due to the accumulation of lipids in hepatocytes, increased aminotransferase levels alongside gastrointestinal symptoms, which can be well managed by dose reductions or treatment suspensions, were noted in the clinical trial.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [158]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“After conducting a successful dose-escalation study [157], a single-arm, open-label, phase 3 study of 29 patients with HoFH showed that lomitapide lowers LDL-C by − 50% and reduces the frequency of lipid apheresis [158].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [158]
In the citing paper
“Given the mechanism of action, these drugs are effective at reducing LDL-C in all patients capable of expressing LDLR in the liver. Therefore, this pharmacological approach is effective in the vast majority of patients, including those with HeFH and, albeit to a lower level, those with HoFH with residual LDLR expression. Receptor-deficient HoFH responds poorly to the therapy [285].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [285]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M.-J., Cromwell, W. C., Lachmann, R. H., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 924
Self-citationInhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580
Self-citationMonogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18925 · Cited by 560
Self-citationGagné, C., Gaudet, D., & Bruckert, E. (2002) · Circulation · doi:10.1161/01.cir.0000018744.58460.62 · Cited by 482
Self-citationMonogenic hypercholesterolemia: new insights in pathogenesis and treatment
Rader, D. J., Cohen, J., & Hobbs, H. H. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318925 · Cited by 450
Self-citationHEART-LIVER TRANSPLANTATION IN A PATIENT WITH FAMILIAL HYPERCHOLESTEROLAEMIA
Starzl, T. E., Bahnson, H. T., Hardesty, R. L., Iwatsuki, S., Gartner, J. C., Bilheimer, D. W., Shaw, B. W., Griffith, B. P., Zitelli, B. J., Malatack, J. J., et al. (1984) · The Lancet · doi:10.1016/s0140-6736(84)91876-2 · Cited by 375
Raal, F. J., Pilcher, G. J., Panz, V. R., van Deventer, H. E., Brice, B. C., Blom, D. J., & Marais, A. D. (2011) · Circulation · doi:10.1161/circulationaha.111.042523 · Cited by 366
Self-citationMicrosomal triglyceride transfer protein
Wetterau, J. R., Lin, M. C. M., & Jamil, H. (1997) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/s0005-2760(96)00168-3 · Cited by 275
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057
Self-citationRaal, F. J., Honarpour, N., Blom, D. J., Hovingh, G. K., Xu, F., Scott, R., Wasserman, S. M., & Stein, E. A. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61374-x · Cited by 734
Self-citationGidding, S. S., Ann Champagne, M., de Ferranti, S. D., Defesche, J., Ito, M. K., Knowles, J. W., McCrindle, B., Raal, F., Rader, D., Santos, R. D., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000297 · Cited by 723
Self-citation
Metadata
- Authors
- Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Du Plessis, A. M., Propert, K. J., Sasiela, W. J., Bloedon, L. T., & Rader, D. J.
- Affiliations
- University of Pennsylvania (US)
- South African Medical Research Council (ZA)
- Western University (CA)
- University of Palermo (IT)
- Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda (IT)
- Cedars-Sinai Medical Center (US)
- Université de Montréal (CA)
- Sapienza University of Rome (IT)
- University of Ferrara (IT)
- Aegerion Pharmaceuticals (United States) (US)
- Corresponding author
- Cuchel, Marina
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 381
- Issue
- 9860
- Pages
- 40-46
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC4587657
- OpenAlex
- W2102238081
- Semantic Scholar
- be4c33fb7141e386bda9c284279062c35f74b06e
- Cited by
- 744
- References
- 27
- Citations by year
- 2026: 36 · 2025: 28 · 2024: 50 · 2023: 40 · 2022: 50 · 2021: 38 · 2020: 34 · 2019: 45 · 2018: 34 · 2017: 60 · 2016: 73 · 2015: 87 · 2014: 97 · 2013: 66
- FWCI
- 82.05
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UpSpace Institutional Repository (University of Pretoria) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Funders
- National Institutes of Health (UL1TR000003)
- National Center for Research Resources (UL1RR024134)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- homozygous familial hypercholesterolemia, lomitapide, microsomal triglyceride transfer protein inhibitor, LDL cholesterol lowering, lipid-lowering therapy, aminotransferase elevation, gastrointestinal adverse effects, drug safety, drug efficacy, dose escalation, liver function monitoring, LDL receptor deficiency
- MeSH terms
- Benzimidazoles, Carrier Proteins, Female, Homozygote, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. https://app.cochat.ai/papers/10.1016/s0140-6736(12)61731-0
- The paper
- Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., Du Plessis, A. M., Propert, K. J., Sasiela, W. J., Bloedon, L. T., & Rader, D. J. (2013). Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. The Lancet. https://doi.org/10.1016/s0140-6736(12)61731-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.